There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. After-hours trades for Unity Biotechnology Inc. (UBX) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.04, or -5.33%, to $0.71. Volume reached 63,696 shares, with price reaching a high of $0.75 and a low of $0.7027. The stock was recently discussed on Yahoo Finance as it revealed that UNITY Biotechnology to Present Clinical Data at the American Society of Retina Specialists (ASRS) 40th Annual Scientific Meeting.
As a NASDAQ listed company, UBX falls under the Healthcare sector while operating within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $0.75 and fluctuated between $0.7700 as its day high and $0.6901 as its day low. The current market capitalization of Unity Biotechnology Inc. is $53.96M. A total of 0.51 million shares were traded on the day, compared to an average of 361.78K shares.
Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, UBX has seen 0 BUY and 5 SELL insider trades, representing the acquisition of 0 and the disposition of 43,457 shares. Over the last 12 months, there were 4 BUYs and 11 SELLs from insiders. Insiders purchased 283,333 shares during that period but sold 100,313.
In the most recent transaction, Ghosh Anirvan sold 10,446 shares of UBX for 0.67 per share on Aug 01. After the transaction, the Chief Executive Officer now owns 996,916 company shares. In a previous transaction on Jun 27, Dananberg Jamie sold 4,398 shares at 0.59 per share. UBX shares that Chief Medical Officer owns now total 672,136.
Among the insiders who sold shares, Ghosh Anirvan disposed of 12,149 shares on Jun 27 at a per-share price of $0.59. This resulted in the Chief Executive Officer holding 1,007,362 shares of UBX after the transaction. In another insider transaction, Dananberg Jamie sold 3,697 shares at $0.62 per share on Jun 21. Company shares held by the Chief Medical Officer now total 676,534.
Investors prefer companies that pay dividends because dividends generate immediate cash flow and indicate a positive outlook.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for UBX in the last 3 months, the mean price target is $7.17 with high estimates of $12.00 and low estimates of $3.00. In terms of 52-week highs and lows, UBX has a high of $3.84 and a low of $0.55.
As of this writing, UBX has an earnings estimate of $-0.28 per share for the current quarter. EPS was calculated based on a consensus of 3 estimates, with a high estimate of $-0.28 per share and a lower estimate of $-0.29. The company reported an EPS of $-0.28 in the last quarter, which was -7.69% lower than expectations of $-0.26.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 6 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for UBX is Overweight with a score of 5.00. A total of 6 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.